Startup HAYA Hauls In $65M to Shed Light on the Dark Genome With a Lead Drug for Heart Failure
Frank Vinluan , 2025-05-08 12:00:00 Many drugs available and in development work by targeting proteins, an approach that comes with limitations. For one, proteins are not the root cause of disease, said Samir Ounzain, co-founder and CEO of HAYA Therapeutics. The driver of disease is the response of cells to their environment. Regulation of this…